- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- Today's Market Action
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Low Interest Rate Investing
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- China's Role as Lender Alters Dynamics for United States
- Israel Going Green
- Inside Wal-Mart's Acai Berry Juice Maker
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
Text Size 
Amgen [AMGN
Loading...
()
] reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.
U.S. sales of the anemia drugs beat analyst estimates for the quarter: Aranesp sold $462 million, compared to projected $398 million; and Epogen sold $638 million, compared to $597 million.
The company also said its closely watched experimental osteoporosis drug denosumab met all goals of a key clinical study, comparing it to a widely used treatment.
The world's biggest biotechnology company by sales posted a quarterly net profit of $835 million, or 76 cents per share, compared with a profit of $833 million, or 71 cents per share, a year ago.
Excluding items, Amgen earned $1 per share. Analysts on average expected 97 cents per share, according to Reuters Estimates.
Amgen shares had lost about a third of their value since the beginning of 2007 as a steady drumbeat of negative news involving its anemia franchise took a heavy toll.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes